EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches



Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches



Seminars in Hematology 36(3): 282-289



The introduction of polychemotherapy and improved radiation techniques has transformed Hodgkin's lymphoma from an incurable disease to a malignancy with one of the highest cure rates. Milestones were the development of the MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimens. Radiotherapy is commonly used, although its precise role has not been defined for patients with advanced-stage disease. More recently, dose-intensified schedules such as Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) were shown to be effective in this group of patients. In particular, the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), in both standard and escalated doses, has produced impressive results in a randomized three-arm study when compared with COPP (cyclophosphamide, vincristine, procarbazine, and prednisone)/ABVD. The significantly higher rates of complete remission (CR) and freedom from treatment failure (FFTF) suggest that the new BEACOPP regimen improves efficacy, but definitive conclusions require further years of follow-up evaluation. Interestingly, BEACOPP abrogates the impact of the newly described seven-factor prognostic scoring system that was reported for patients treated with MOPP/ABVD or similar regimens. The prognostic index includes factors such as serum albumin, hemoglobin, male sex, stage IV disease, age more than 45 years, white blood cell count, and lymphocyte count. Whereas patients with Hodgkin's lymphoma have a good prognosis on first diagnosis, those with relapsed or refractory disease face a poor outcome.

(PDF 0-2 workdays service: $29.90)

Accession: 035980853

Download citation: RISBibTeXText

PMID: 10462328



Related references

Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. Cancer Investigation 24(7): 713-717, 2006

Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?. Cancer Investigation 24(4): 461-465, 2006

Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma. Cmaj 136(1): 29-36, 1987

Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification. Cancer Journal 24(5): 230-236, 2018

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology 12(7): 1366-1374, 1994

Treatment of advanced malignant lymphoma part 1. combination chemotherapy for advanced non hodgkin's lymphoma with adriamycin vincristine ifosfamide and prednisolone. Okayama Igakkai Zasshi 97(3-4): 249-262, 1985

Tailored BEACOPP regimen for standard and high risk Hodgkin lymphoma based on early response to Ga67 scintigraphy and the international prognostic score for advanced Hodgkin disease. Blood 98(11 Part 2): 240b, November 16, 2001

Malignant lymphoma. Advances in diagnosis and treatment. III. Practice of diagnosis (Standard therapy). 1. Standard therapy of malignant lymphoma (Hodgkin's disease and non-Hodgkin's lymphoma ). Nihon Naika Gakkai Zasshi 90(6): 997-1002, 2001

Standard therapy of advanced Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program: 497-506, 2010

Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opinion on PharmacoTherapy 15(8): 1139-1151, 2014

Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: a retrospective analysis. Journal of Huazhong University of Science and Technology. Medical Sciences 34(2): 260-264, 2014

Standard treatment of malignant lymphoma (Hodgkin's and non-Hodgkin's lymphoma). Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 90(6): 997-1002, 2001

Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?. Transfusion and Apheresis Science 37(1): 37-41, 2007

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 328(14): 1002-1006, 1993

CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation). Japanese Journal of Clinical Hematology 25(2): 164-168, 1984